ES2974073T3 - Uso terapéutico del afatinib en el cáncer - Google Patents

Uso terapéutico del afatinib en el cáncer

Info

Publication number
ES2974073T3
ES2974073T3 ES19742015T ES19742015T ES2974073T3 ES 2974073 T3 ES2974073 T3 ES 2974073T3 ES 19742015 T ES19742015 T ES 19742015T ES 19742015 T ES19742015 T ES 19742015T ES 2974073 T3 ES2974073 T3 ES 2974073T3
Authority
ES
Spain
Prior art keywords
afatinib
cancer
therapeutic use
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19742015T
Other languages
English (en)
Inventor
Calonge Jordi Surralles
Pedreno Jordi Minguillon
Escribano Helena Montanuy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat Autonoma de Barcelona UAB
Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBEREHD
Fundacio Institut de Recerca de lHospital de La Santa Creu i Sant Pau
Consorcio Centro de Investigacion Biomedica en Red MP
Original Assignee
Universitat Autonoma de Barcelona UAB
Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBEREHD
Fundacio Institut de Recerca de lHospital de La Santa Creu i Sant Pau
Consorcio Centro de Investigacion Biomedica en Red MP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat Autonoma de Barcelona UAB, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBEREHD, Fundacio Institut de Recerca de lHospital de La Santa Creu i Sant Pau, Consorcio Centro de Investigacion Biomedica en Red MP filed Critical Universitat Autonoma de Barcelona UAB
Application granted granted Critical
Publication of ES2974073T3 publication Critical patent/ES2974073T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES19742015T 2018-07-16 2019-07-15 Uso terapéutico del afatinib en el cáncer Active ES2974073T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382527.2A EP3597193A1 (en) 2018-07-16 2018-07-16 Therapeutic use of afatinib in cancer
PCT/EP2019/069039 WO2020016191A1 (en) 2018-07-16 2019-07-15 Therapeutic use of afatinib in cancer

Publications (1)

Publication Number Publication Date
ES2974073T3 true ES2974073T3 (es) 2024-06-25

Family

ID=62981154

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19742015T Active ES2974073T3 (es) 2018-07-16 2019-07-15 Uso terapéutico del afatinib en el cáncer

Country Status (4)

Country Link
US (1) US20210290622A1 (es)
EP (2) EP3597193A1 (es)
ES (1) ES2974073T3 (es)
WO (1) WO2020016191A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115671112A (zh) * 2022-07-29 2023-02-03 中南民族大学 阿法替尼在防治二型糖尿病中的新用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016001844A1 (en) * 2014-06-30 2016-01-07 Sun Pharmaceutical Industries Limited Amorphous form of afatinib dimaleate
CA2991868A1 (en) * 2015-07-31 2017-02-09 Vascular Biogenics Ltd. Motile sperm domain containing protein 2 and cancer

Also Published As

Publication number Publication date
US20210290622A1 (en) 2021-09-23
EP3846819B1 (en) 2024-01-03
WO2020016191A1 (en) 2020-01-23
EP3597193A1 (en) 2020-01-22
EP3846819A1 (en) 2021-07-14

Similar Documents

Publication Publication Date Title
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CY1124955T1 (el) Pd-1 αντισωματα
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
ES2973114T3 (es) Inhibidores heterobicíclicos de MAT2A y métodos de uso para el tratamiento del cáncer
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
DK3737264T3 (da) Bærbar stol
CL2018003444A1 (es) Derivados de adenosina para uso en el tratamiento del cancer.
DOP2017000035A (es) Inhibidores de la proteina quinasa c y metodos de su uso
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2016001743A1 (es) Conjugados de anticuerpo-fármaco (adc) de duocarmicina para su uso en el tratamiento de cáncer de endometrio.
CL2016003260A1 (es) Profármacos de gemcitabina
CL2016001840A1 (es) Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
CO2020015923A2 (es) Antagonista de gremlin-1 para la prevención y tratamiento del cáncer
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
DK3532067T3 (da) Liposomal formulering til anvendelse til behandling af cancer
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
DK3253208T3 (da) Kombinationsterapier til anvendelse i behandlingen af brystcancer
MA52627A (fr) Traitement du cancer
ES2974073T3 (es) Uso terapéutico del afatinib en el cáncer
DK3917538T3 (da) Deoxycytidinderivater til anvendelse i cancerterapier